Module

Customizing HCV Therapy With Current Agents: Optimizing Patient Outcomes

Source: Hepatitis Annual Update 2006

Customizing HCV Therapy With Current Agents: Optimizing Patient Outcomes

Program Director: Emmet B. Keeffe, MD, MACP

Faculty:

Mark S. Sulkowski, MD

CME CREDIT INFORMATION

Release Date: 08/01/06

Expiration Date: 07/31/07

Physicians: maximum of 1.25 AMA PRA Category 1 Credits™

Registered Nurses: 1.5 Nursing CE credits

Pharmacists: 1.2 contact hours (0.12 CEUs)

Status: Please log in to view status

Learning Objectives

Upon completion of this activity, participants should be able to:

Describe general principles of individualizing therapy based on patient and viral characteristics
Recount factors or markers that are predictive of HCV treatment success
Discuss specific strategies for optimizing treatment, such as longer treatment for genotype 1 and shorter treatment for genotype 2/3

Topics covered include:

Introduction
Identification of Early Virologic Nonresponse: Predicting Failure
Early Virologic Response for Predicting Treatment Success
Treatment Duration in Persons With RVR: Is Shorter Treatment an Option? Data in Genotypes 2 and 3
Treatment Duration in Persons With RVR: Is Shorter Treatment an Option? Data in Genotype 1
Treatment Duration in Persons With Slow Viral Response: Is Longer Treatment Beneficial?
Conclusions

Disclaimer: The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.